Evidence Files

Omega-3: The Heart Health Revolution That the 2018 Trials Quietly Complicated

Cochrane pooled 86 trials across 162,796 people and concluded, at high certainty, that omega-3 supplements have little or no effect on all-cause mortality. In the same year, a prescription formulation at a much higher dose cut cardiovascular events from 22.0% to 17.2% in a specific group of patients. Both results are correct — and the entire fish oil market lives in the gap between them.

Published: 20 June 2026

Verdict

TREATMENT (partially confirmed)

We searched PubMed and Cochrane Library for omega-3 evidence. The largest review pooled 86 randomised trials and 162,796 participants: the effect on all-cause mortality was RR 0.97, meaning essentially none — and that is graded high-certainty evidence. There is a small reduction in coronary heart disease mortality, and triglycerides do fall. By contrast REDUCE-IT, testing 4 g/day of prescription purified EPA in patients with elevated triglycerides already on statins, found events dropped from 22.0% to 17.2%. The answer depends not on the words "omega-3" but on the dose, the form, and who is taking it.

How the consensus formed — and cracked

The omega-3 story started with a 1970s study of Greenlandic Inuit who ate large amounts of fatty fish and had low rates of heart disease. The hypothesis: omega-3 fatty acids protect the cardiovascular system. Early trials seemed to confirm it. The GISSI-Prevenzione trial (1999, Italy) showed reduced cardiac death after heart attack. Enthusiasm was high.

Then came the scaling-up era — trials enrolling tens of thousands of participants. VITAL randomised 25,871 adults and followed them a median of 5.3 years: major cardiovascular events occurred in 386 people on omega-3 versus 419 on placebo, a difference that was not statistically significant (p = 0.24). Cancer incidence didn't move either. The authors' conclusion is blunt: supplementation did not lower the incidence of major cardiovascular events or cancer.

The effect that looked strong in early studies attenuated as research quality improved. This pattern — large effects in early trials, shrinking effects in larger, better-controlled trials — is a well-recognised sign of publication bias and early-trial overestimation, and the Cochrane review that pooled everything is where it becomes unmistakable.

Where the evidence actually stands

Omega-3 isn't one question but several, so the figures are best kept separate by indication.

All-cause mortality: essentially no effect — and this is the most reliable thing we know. The Cochrane review pooled 86 trials and 162,796 participants for a risk ratio of 0.97 (95% CI 0.93–1.01), graded high-certainty evidence — the strongest reliability tier there is
There is a small reduction in coronary heart disease mortality. The same review finds moderate reductions in cardiovascular mortality (RR 0.92) and events (RR 0.96): real, modest, and held at lower certainty than the headline result
In healthy people, nothing was found at all. VITAL, 25,871 participants: 386 events versus 419 on placebo, p = 0.24. This is the direct answer to "should a healthy person take fish oil for prevention"
Prescription-dose EPA is a genuinely different conversation. REDUCE-IT: 8,179 patients with elevated triglycerides already taking statins received 4 g/day of purified EPA. The primary endpoint occurred in 17.2% versus 22.0% on placebo — a large, convincing difference, in a narrowly defined group, at a dose no retail capsule contains
Triglycerides do fall — both sources agree. If that is the specific goal and a clinician set it, omega-3 has a role. But triglycerides are an intermediate marker, not in themselves a demonstrated rescue from heart attacks

Over-the-counter fish oil vs. prescription omega-3

Standard supplement (1g/day, ~300mg EPA+DHA)

Sold for heart health, brain health, inflammation. Roughly the dose across the trials Cochrane pooled, where all-cause mortality didn't move at high certainty. Read the back of the bottle: "1000 mg fish oil" and "1000 mg omega-3" are not the same claim.

Prescription-dose EPA (4g/day)

REDUCE-IT studied purified EPA in patients with high triglycerides already on statins: events fell from 22.0% to 17.2%. A specific drug, a specific dose, a specific population — and roughly thirteen times the EPA in a standard capsule.

Frequently asked questions

Should a healthy person take fish oil for prevention?

There is no convincing case for it. VITAL, with nearly 26,000 participants, found no reduction in major cardiovascular events (p = 0.24), and the Cochrane review of 162,796 people showed at high certainty that supplements have little or no effect on all-cause mortality. That is among the most reliable findings in the entire supplement literature.

Then why did REDUCE-IT produce such a striking result?

Because it tested a different thing in a different population. The dose was 4 grams of purified EPA — around thirteen times the EPA in a typical 300 mg EPA+DHA capsule — given not to the general public but to patients with elevated triglycerides who were already on statins. Transferring that result to a bottle of fish oil on a shelf is not a fair read.

How much EPA and DHA should a capsule contain?

The main skill here is reading the label, because "1000 mg fish oil" and "1000 mg omega-3" describe different things. A typical 1000 mg fish oil capsule contains roughly 300 mg of EPA+DHA combined. That is the number that matters, and it is usually printed in small type on the back.

Is eating fish better than taking a supplement?

For most people, yes. Two portions of oily fish a week deliver omega-3 alongside protein, iodine, selenium and vitamin D, and they sit in dietary guidelines in a way capsules for healthy adults do not. A supplement earns its place when someone doesn't eat fish at all, or when a clinician has set a specific target.

What about omega-3 for brain, joints or skin?

Those claims rest on a far thinner evidence base than the cardiovascular ones — typically small trials and intermediate markers rather than hard clinical outcomes. A label promising benefits for heart, brain, joints, vision and skin at once is describing a marketing strategy, not a demonstrated range of effects.

Our Conclusion

Omega-3 is neither a scam nor a sugar pill, but "good for your heart" turned out to be too broad a claim to survive testing. The most reliable finding available is 86 trials across 162,796 people concluding, at high certainty, that supplements barely touch all-cause mortality. The most striking is REDUCE-IT, cutting events from 22% to 17%. These don't contradict each other: the second used 4 grams of prescription purified EPA — roughly thirteen times the active ingredient in a standard capsule — in patients with elevated triglycerides already on statins. Practically, that means one thing. If your triglycerides are high, omega-3 is worth discussing with a clinician, and the conversation will be about dose and form. If you're healthy and taking fish oil for prevention, the large independent trials found no grounds for it — and two portions of oily fish a week deliver the same thing plus protein, iodine and vitamin D.

Sources

Every claim in this article rests on a primary publication. Links go to the publisher's site or to PubMed, the US National Library of Medicine database.

This article is for informational purposes only and does not constitute medical advice. Trick or Treatment analyses the presence of clinical studies in open scientific databases — PubMed and Cochrane Library. The absence of studies in these databases does not automatically mean a drug is ineffective, but it does mean its effectiveness has not been confirmed by evidence-based medicine standards. Any treatment decisions should be made together with your doctor.